Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 Apr 16;108(7):1515-24.
doi: 10.1038/bjc.2013.116. Epub 2013 Mar 21.

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

B Makubate  1 , P T Donnan, J A Dewar, A M Thompson, C McCowan
Affiliations

Cohort study of adherence to adjuvant endocrine therapy, breast cancer recurrence and mortality

B Makubate et al. Br J Cancer. .

Abstract

Background: Adjuvant endocrine therapy is recommended for women with oestrogen receptor-positive breast cancer, but many women do not take the medication as directed and they stop treatment before completing the standard 5-year duration.

Methods: This retrospective cohort study conducted between 1993 and 2008 of all women with incident breast cancer, who are residing in the Tayside region of Scotland, examined adherence to prescribed adjuvant tamoxifen or aromatase inhibitors (AIs). Survival analysis examined the effect of adherence on all-cause mortality, breast cancer death and recurrence, using linked prescribing, cancer registry, clinical cancer audit, hospital discharge and death records.

Results: A total of 3361 women with breast cancer were followed for a median 4.47 years (interquartile range (IQR)=2.04-8.55). The median overall adherence was 90% (IQR=90-100%), but the annual adherence reduced after a longer period from diagnosis. Low adherence of <80% was associated with poorer survival (hazard ratios=1.20; 95% confidence interval=1.03-1.40, P=0.019). There was no significant difference for low adherence over the treatment period and recurrence, or breast cancer death, but patients with high annual adherence for 5 years had better outcomes than those with 3 or less.

Conclusion: Low adherence to all adjuvant endocrine therapy for women with breast cancer, whether tamoxifen or AI, increases the risk of death.

PubMed Disclaimer

References

    1. Barron TI, Connolly R, Bennett K, Feely J, Kennedy MJ. Early discontinuation of tamoxifen. Cancer. 2007;109 (5:832–839. - PubMed
    1. Bradburn MJ, Clark TG, Love SB, Altman DG. Survival analysis part II: multivariate data analysis – an introduction to concepts and methods. Br J Cancer. 2003;89 (3:431–436. - PMC - PubMed
    1. Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010;11 (12:1135–1141. - PubMed
    1. Demissie S, Silliman RA, Lash TL. Adjuvant tamoxifen: predictors of use, side effects, and discontinuation in older women. J Clin Oncol. 2001;19 (2:322–328. - PubMed
    1. Dezentje VO, van Blijderveen NJC, Gelderblom H, Putter H, van Herk-Sukel MPP, Casparie MK, Egberts ACG, Nortier JWR, Guchelaar H-J. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28 (14:2423–2429. - PubMed

Publication types